SC-53228

SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis^[1][2]. In Vivo:SC-53228 (20 mg/kg, p.o., twice daily for 56 days) demonstrates significant anti-inflammatory effects and excellent safety in the spontaneous colitis model of cotton-topped marmosets^[1].
SC-53228 (100-1000 μg or 1% gel, topical administration; 2.5-10 mg/kg (mice), 40 mg/kg (monkey) p.o., single dose or once daily for 5 days) demonstrates significant anti-inflammatory effects in the psoriasis models of mice, guinea pigs, and rhesus monkeys and both local and oral administration could rapidly inhibit inflammation^[2].